Authorized psychiatrists in Australia have been able to prescribe psilocybin for treatment-resistant depression since July 2023.
Filament Health Corp. said it successfully completed an export of PEX010, the company’s botanical-psilocybin drug candidate, to Perth, Western Australia.
Filament Health, a clinical‐stage company focusing on psychedelic drugs that are naturally extracted from plants and fungi, said the shipment likely is the first botanical psilocybin to be exported Australia.
Reset Mind Sciences, a psychedelic-focused subsidiary of Little Green Pharma, received the shipment, and plans to use Filament’s drug product for research purposes, according to Vancouver-based Filament Health.
“The successful export of PEX010 to Australia is a major achievement for our team and demonstrates our significant regulatory capabilities,” said Lisa Ranken, chief operating officer at Filament Health. “To our knowledge, this is the first legal shipment of a botanical-psilocybin drug candidate to arrive in Australia, and we are pleased to see a natural option being explored by Australian researchers.”
Reset Chief Operating Officer Dr Leon Warne called the shipment “not only a significant milestone for Reset but also for Australia’s burgeoning psilocybin industry.”
Since July 1, 2023, authorized psychiatrists in Australia have been able to prescribe psilocybin for treatment-resistant depression.
Reset is progressing its GMP license application to manufacture psilocybin products for human consumption from botanically sourced psilocybin while the industry awaits publication of the Australian Therapeutic Goods Administration’s Therapeutic Goods Order governing psilocybin production in Australia.